Collegium Pharmaceutical Analyst Price Targets

Wall Street analyst price targets and consensus rating for Collegium Pharmaceutical (COLL).

Price Target Range — 10 Quarters

Analyst Consensus — 8 Analysts

7Buy

1Hold

Consensus RatingBuy# Analysts8Avg. Consensus PT$47Upside to Avg. PT+105.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 23, 2026	Oppenheimer	Les Sulewski	Initiate	Outperform	$50
Sep 9, 2026	Truist Securities	Alexander Xenakis	PT Cut	Buy	$58→$49
Sep 9, 2026	Leerink Partners	Daniel Clark	Initiate	Outperform	$45
Aug 19, 2026	Barclays	Glen Santangelo	PT Cut	Overweight	$56→$48
Aug 7, 2026	Piper Sandler	David Amsellem	PT Cut	Neutral	$45→$43
Aug 6, 2026	Needham	Serge Belanger	PT Cut	Buy	$56→$46
Mar 20, 2026	HC Wainwright & Co.	Brandon Folkes	Maintained	Buy	$60
Mar 19, 2026	Needham	Serge Belanger	PT Raise	Buy	$54→$56
Feb 26, 2026	Needham	Serge Belanger	PT Cut	Buy	$56→$54
Jan 9, 2026	Barclays	Glen Santangelo	PT Cut	Overweight	$58→$56
Jan 9, 2026	HC Wainwright & Co.	Brandon Folkes	PT Raise	Buy	$46→$60
Jan 8, 2026	Needham	Serge Belanger	PT Raise	Buy	$48→$56
Dec 9, 2025	Barclays	Glen Santangelo	Initiate	Overweight	$58
Nov 7, 2025	Truist Securities	Les Sulewski	PT Raise	Buy	$45→$48
Nov 7, 2025	HC Wainwright & Co.	Brandon Folkes	PT Raise	Buy	$44→$46
Oct 28, 2025	Needham	Serge Belanger	Maintained	Buy	$46
Aug 11, 2025	HC Wainwright & Co.	Brandon Folkes	Assumes	Buy	$44
May 9, 2025	Piper Sandler	David Amsellem	PT Raise	Neutral	$36→$37
Apr 9, 2025	Needham	Serge Belanger	Maintained	Buy	$46
Mar 24, 2025	HC Wainwright & Co.	Oren Livnat	Maintained	Buy	$50

Analyst Ratings News

PRO
Oppenheimer Initiates Coverage On Collegium Pharmaceutical with Outperform Rating, Announces Price Target of $50

Oppenheimer analyst Les Sulewski initiates coverage on Collegium Pharmaceutical (NASDAQ:COLL) with a Outperform rating and announces Price Target of $50.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $49

Truist Securities analyst Alexander Xenakis maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and lowers the price target from $58 to $49.

Benzinga Newsdesk

PRO
Leerink Partners Initiates Coverage On Collegium Pharmaceutical with Outperform Rating, Announces Price Target of $45

Leerink Partners analyst Daniel Clark initiates coverage on Collegium Pharmaceutical (NASDAQ:COLL) with a Outperform rating and announces Price Target of $45.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Collegium Pharmaceutical, Lowers Price Target to $48

Barclays analyst Glen Santangelo maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Overweight and lowers the price target from $56 to $48.

Benzinga Newsdesk

PRO
Piper Sandler Reiterates Neutral on Collegium Pharmaceutical, Lowers Price Target to $43

Piper Sandler analyst David Amsellem reiterates Collegium Pharmaceutical (NASDAQ:COLL) with a Neutral and lowers the price target from $45 to $43.

Benzinga Newsdesk

PRO
Needham Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $46

Needham analyst Serge Belanger maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and lowers the price target from $56 to $46.

Benzinga Newsdesk

Collegium Pharmaceutical Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Collegium Pharmaceutical Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Oppenheimer Initiates Coverage On Collegium Pharmaceutical with Outperform Rating, Announces Price Target of $50

PRO
Truist Securities Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $49

PRO
Leerink Partners Initiates Coverage On Collegium Pharmaceutical with Outperform Rating, Announces Price Target of $45

PRO
Barclays Maintains Overweight on Collegium Pharmaceutical, Lowers Price Target to $48

PRO
Piper Sandler Reiterates Neutral on Collegium Pharmaceutical, Lowers Price Target to $43

PRO
Needham Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $46

People Also Watch

People Also Watch

Collegium Pharmaceutical Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Collegium Pharmaceutical Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROOppenheimer Initiates Coverage On Collegium Pharmaceutical with Outperform Rating, Announces Price Target of $50

PROTruist Securities Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $49

PROLeerink Partners Initiates Coverage On Collegium Pharmaceutical with Outperform Rating, Announces Price Target of $45

PROBarclays Maintains Overweight on Collegium Pharmaceutical, Lowers Price Target to $48

PROPiper Sandler Reiterates Neutral on Collegium Pharmaceutical, Lowers Price Target to $43

PRONeedham Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $46

People Also Watch

People Also Watch

PRO
Oppenheimer Initiates Coverage On Collegium Pharmaceutical with Outperform Rating, Announces Price Target of $50

PRO
Truist Securities Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $49

PRO
Leerink Partners Initiates Coverage On Collegium Pharmaceutical with Outperform Rating, Announces Price Target of $45

PRO
Barclays Maintains Overweight on Collegium Pharmaceutical, Lowers Price Target to $48

PRO
Piper Sandler Reiterates Neutral on Collegium Pharmaceutical, Lowers Price Target to $43

PRO
Needham Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $46